Aiforia's new clinical AI solution for gastric cancer diagnostics

Translation: Original published in Finnish on 02/03/2026 at 07:00 am EET

Aiforia announced on Monday that it has released a new CE-IVD-marked AI solution for gastric cancer diagnostics. The Aiforia® Gastric Cancer AI application is designed to support pathologists in the detection and reporting of gastric cancer. We believe it strengthens the company's position as a market leader in clinical digital pathology in Europe. We consider the announcement a logical continuation of the company's strategy to expand its clinical product portfolio and leverage its new Foundation Engine technology.

The product portfolio expands to gastric cancer diagnostics

The Aiforia® Gastric Cancer AI application is a CE-IVD marked clinical solution under the IVDR regulation. The application is designed to support a high-sensitivity diagnostic approach, helping pathologists identify particularly hard-to-detect gastric cancer types, whose tumor cells can be scattered and difficult to distinguish in routine examination. Gastric cancer is one of the leading causes of cancer deaths worldwide, so accurate diagnostics are of great importance for patient care.

Technically, the new application is based on Aiforia's Foundation Engine technology, which has been developed to operate reliably even in volatile real-world situations, such as variations in sample quality or staining. The solution is integrated into the company's Clinical Suite Viewer interface, which allows for its seamless integration into existing digital pathology workflows

Product portfolio expanding according to plan

The announcement of the new clinical application came as no surprise, as Aiforia has communicated its goal to significantly expand its clinical offering. The company aims to achieve around 80% coverage of the pathologist's diagnostic workflow by 2030. We consider the announcement a positive sign that the company's product development pipeline is operating efficiently with the support of the Foundation Engine technology, launched in late 2025, which we commented on earlier here.

Expanding the product portfolio is critical to Aiforia's growth strategy, as it enables larger deal sizes and the expansion of existing customer accounts. It also mitigates risks related to the company's ability to maintain a rapid pace of innovation after previously implemented cost savings. We believe Aiforia has already achieved a strong market position by winning a significant share of new clinical customers, and new product launches will further strengthen this position.

No immediate effect on estimates

Although the new gastric cancer diagnostics solution strengthens Aiforia's competitiveness and clinical product portfolio, it does not lead to revisions in our estimates. Our estimates already consider that the clinical product portfolio is constantly expanding, and revenue growth will accelerate, supported by this, in the coming years. Aiforia's revenue growth largely relies on the ramp-up of clinical customers and the growth of customer-specific invoicing, which a broader product offering enables.